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Purpose: Acute COPD exacerbations account for much of the rising disability and costs 
associated with COPD, but data on predictive risk factors are limited. The goal of the current 
study was to develop a robust, clinically based model to predict frequent exacerbation risk.
Patients and methods: Patients identified from the Optimum Patient Care Research Database 
(OPCRD) with a diagnostic code for COPD and a forced expiratory volume in 1 second/forced 
vital capacity ratio ,0.7 were included in this historical follow-up study if they were $40 years 
old and had data encompassing the year before (predictor year) and year after (outcome year) 
study index date. The data set contained potential risk factors including demographic, clinical, 
and comorbid variables. Following univariable analysis, predictors of two or more exacerbations 
were fed into a stepwise multivariable logistic regression. Sensitivity analyses were conducted 
for subpopulations of patients without any asthma diagnosis ever and those with questionnaire 
data on symptoms and smoking pack-years. The full predictive model was validated against 
1 year of prospective OPCRD data.
Results: The full data set contained 16,565 patients (53% male, median age 70 years), includ-
ing 9,393 patients without any recorded asthma and 3,713 patients with questionnaire data. The 
full model retained eleven variables that significantly predicted two or more exacerbations, of 
which the number of exacerbations in the preceding year had the strongest association; others 
included height, age, forced expiratory volume in 1 second, and several comorbid conditions. 
Significant predictors not previously identified included eosinophilia and COPD Assessment 
Test score. The predictive ability of the full model (C statistic 0.751) changed little when applied 
to the validation data set (n=2,713; C statistic 0.735). Results of the sensitivity analyses sup-
ported the main findings.
Conclusion: Patients at risk of exacerbation can be identified from routinely available, com-
puterized primary care data. Further study is needed to validate the model in other patient 
populations.
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Introduction
COPD is a serious, debilitating condition that has become a major public health 
concern and by 2020 is projected to rank fifth in global burden of disease and third in 
global mortality.1 For a proportion of patients, COPD is a progressive disease char-
acterized by periodic acute exacerbations of symptoms. These exacerbations pose an 
immediate threat to patients and also hasten progression of the disease. Exacerbations 
accelerate decline of lung function, so that patients often fail to return to baseline 
levels. Although symptoms may last a few days, recovery of lung function can take 
weeks to months, resulting in prolonged periods of functional limitation and general 
worsening of quality of life, often with some degree of permanent functional decline. 
Exacerbations are also associated with substantial risk of hospitalization and death, 
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as well as considerable economic costs that increase with 
exacerbation frequency.1,2
Preventing exacerbations is therefore a key goal of COPD 
management1,3–5 and hence the need to predict who are likely 
to experience exacerbations. The recent Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) categories A–D 
were developed to aid in assessing future risk of exacerba-
tions and performed well in one study;6,7 however, patient 
assignment to categories may vary depending on the choice 
of symptom measure, limiting their applicability.8 Indices 
of COPD severity such as the body mass index [BMI], 
obstruction, dyspnea, and exercise (BODE) index and the 
age, dyspnea, and obstruction (ADO) index have been used to 
try to predict future exacerbations among patients with COPD 
but with only moderate (60%–70%) prediction success; 
moreover, they require specific data (eg, 6-minute walk test) 
that may not be routinely available.9,10 The dyspnea, airflow 
obstruction, smoking status, and exacerbation frequency 
(DOSE) index has been shown to predict future exacerbations 
in a large primary care data set, and the index was stronger 
than previous exacerbation frequency or the ADO or BODE 
index.9,11,12 Other researchers have developed de novo sta-
tistical models to identify independent clinical predictors. 
However, many of these studies included relatively small 
sample sizes,10,13–16 patients with severe COPD,14,17,18 and/or 
severe outcomes such as hospitalization or death.13,15,17,19–22
The goal of the current study was to develop a robust, 
clinically based predictive model that would encompass 
all levels of COPD severity as well as moderate or severe 
exacerbation severity. Such a model could help in earlier 
targeting of patients for review to optimize drug therapy 
and other interventions, with the aim of reducing hospital 
admissions, decline in lung function, and the morbidity and 
mortality associated with COPD. A secondary objective 
was to compare the model’s predictive value in relation to 
existing predictive tools.
Patients and methods
This was a historical follow-up study of patients with COPD 
identified from the Optimum Patient Care Research Database 
(OPCRD).23 The OPCRD is a quality-controlled, longitudinal, 
respiratory-focused database containing anonymous data 
from general practices in the UK and has been approved by 
the Trent Multicentre Research Ethics Committee for clinical 
research use (approval reference 10/H0405/3), and this study 
was approved by the Anonymised Data Ethics Protocols and 
Transparency committee, the independent scientific advi-
sory committee for the OPCRD. Informed consent was not 
required or possible as we worked with anonymous data, and 
this was not an interventional study. However, patients could 
opt out of having their data used in research. At the time of 
the study, the OPCRD contained records of .50,000 patients 
with COPD from .300 UK general practices. The database 
combines routine data from electronic patient records with 
linked patient-reported data collected using disease-specific 
questionnaires. Routine clinical data, including patient demo-
graphic characteristics, comorbidities, exacerbation history, 
modified Medical Research Council (mMRC) score,24 and 
current therapy, were extracted from primary care practice 
management systems. In addition, a proportion of patients 
with relevant disease codes were invited to complete validated 
disease assessment questionnaires, sent via a secure mailing 
house. The questionnaires enabled calculation of the mMRC 
scores and the COPD Assessment Test (CAT) scores.25
The current study was divided into model-building 
and model-validation components. Patients were eligible 
for inclusion in the model-building phase if, on or before 
March 12, 2013, they had at least one recorded eosinophil 
count, were at least 40 years of age, had been diagnosti-
cally coded for COPD, and had a forced expiratory volume 
in 1 second/forced vital capacity (FEV
1
/FVC) ratio ,0.7 
recorded within 5 years of their last eosinophil count 
(defined as the index date). All eligible patients needed to 
have at least 1 year of observation before (baseline year) 
and 1 year after (outcome year) the index date. Included 
patients also needed to have complete data on the candi-
date predictors analyzed. Those with chronic respiratory 
diseases other than asthma, such as bronchiectasis, were 
excluded. The validation cohort consisted of patients with 
similar eligibility criteria identified between March 2013 
and February 2014.
Potentially important variables within the OPCRD were 
identified from a search of the literature and from expert 
opinion of the authors:
•	 Sociodemographic factors: sex, age, height, weight, BMI, 
smoking status
•	 Symptom severity: mMRC dyspnea score, CAT score, 
number of exacerbations in the previous year
•	 Comorbidities: asthma, eczema, allergic or nonallergic 
rhinitis, nasal polyps, diabetes mellitus, gastroesophageal 
reflux disease (GERD), ischemic heart disease, heart fail-
ure, anxiety/depression, Charlson comorbidity index
•	 Spirometry: FEV
1
 (% predicted), FEV
1
/FVC ratio
•	 Peripheral blood eosinophilia (defined as $500 cells/µL).
Model building
To enhance diagnostic specificity and to be consistent with 
earlier research, as well as with the GOLD cut-point for 
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risk of future events,7 we defined the outcome of interest as 
frequent ($2) exacerbations. Exacerbations were defined 
as either 1) unscheduled hospital admission or accident/
emergency attendance for COPD or lower respiratory 
events, 2) an acute course of oral corticosteroids prescribed 
with evidence of respiratory review, or 3) antibiotics 
prescribed with evidence of respiratory review. Where 
one or more oral corticosteroid course, hospitalization, or 
antibiotic prescription occurred within a 2-week window, 
these events were considered to be the result of the same 
exacerbation.
All analyses were performed using the R statistical 
package (version 3.0.2). Prior to analysis, continuous 
variables were evaluated via likelihood ratio test to see 
if quadratic or cubic transformation improved model fit. 
Akaike information criteria (AIC) were compared to test 
whether model fit was improved by categorical or continu-
ous classification.
Univariable logistic regressions were performed to gauge 
the importance of individual variables and to help define 
the best form (eg, continuous, categorical) of each variable. 
However, all potentially important variables were fed into a 
multiple logistic regression with backward selection of the 
model having the lowest AIC. The questionnaire variables 
dealing with symptoms and pack-years were excluded from 
this analysis owing to small sample size.
By way of sensitivity analysis, the model-building 
process was repeated for two different subpopulations. Sub-
population 1 consisted of all patients without an overlapping 
diagnosis of asthma, defining asthma using the sensitive 
definition of any asthma-related Read code at any time in 
the data set. The second, smaller subpopulation consisted of 
those with questionnaire information on symptoms (CAT and 
mMRC score) and pack-years of smoking.
Model validation
Calibration plots were performed by comparing observed 
with predicted risk among 150 groups of ~110 patients 
each. Goodness of fit was judged using both the C statistic 
(area under the curve) and the Hosmer–Lemeshow test.26 
The C statistic confidence intervals (CIs) were generated 
by bootstrapping. External validity was judged by the 
C statistic when the full multivariable model was applied to 
the validation cohort.
In addition, we assessed the predictive accuracy of 
the model to predict two or more exacerbations compared 
with the DOSE index and GOLD categories A–D using the 
mMRC, together with exacerbations and FEV
1
, to assign 
categories.7
Results
Approximately 51,000 patients with COPD were identified 
from the OPCRD; 16,565 met all inclusion criteria. The main 
reasons for exclusion from the study are depicted in Figure 1. 
The study index dates (ie, dates of last eosinophil count) 
ranged from 1993 to 2012 (median year, 2009; interquartile 
range, 2007–2010).
Of the 16,565 patients included in the full population, 
9,393 did not have any recorded asthma Read code at any 
time (subpopulation 1) and 3,713 had questionnaire data for 
determining CAT score (subpopulation 2). The characteris-
tics of these three populations (Table 1) and the frequencies of 
COPD exacerbations (Table 2) were similar, with only minor 
differences. Most patients had moderate COPD, and 92% of 
lung function measurements were taken within 2 years of the 
index date (80% within 1 year).
Patient numbers for the categorized mMRC and DOSE 
index scores and for GOLD category are in Table S1.
Approximately 20% of the total population had two or 
more exacerbations in the outcome year (Table 2). Most 
variables were significant univariable predictors (Table 3).
The final multivariable model contained eleven variables, 
of which the number of exacerbations in the preceding year 
had the strongest association. Most other variables were 
associated with relatively modest odds ratios (ORs) (Table 4). 
The overall C statistic for the model was 0.751 (95% CI 
0.742–0.761) (Figure 2). The Hosmer–Lemeshow test had 
a P-value of 0.30, suggesting no significant departures from 
goodness of fit. The model and a patient example are included 
in the Supplementary material.
The model developed using the asthma-free subset (sub-
population 1) was very similar to that for the full population 
(with the obvious exception of asthma) and had similar 
ORs (Table 5). The smaller subset of patients for whom 
CAT questionnaire data were available (subpopulation 2) 
also produced a similar model, although several variables 
important to the full data set were no longer retained in 
the subpopulation 2 model. This latter model included two 
additional variables (CAT score and female sex) not in the 
full model, but including these variables did not apprecia-
bly alter the C statistic for the full model. Age was a much 
stronger risk factor in subpopulation 2 than in the other 
models (Table 5).
Model validation
Summary measures of internal validity were unremarkable 
and suggested adequate fit and predictive ability for the 
full-population model. Applying the full-population model 
to the validation data set (N=2,713; baseline characteristics 
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Figure 1 Patient selection in the database.
Abbreviations: BMI, body mass index; CaT, COPD assessment Test; OPCrD, Optimum Patient Care research Database; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity.
in Table S2) resulted in a C statistic of 0.735 (95% CI 
0.713–0.757), suggesting good external validity within the 
validation cohort (Figure 3).
Comparison of the model with other 
indices
The DOSE index score (Table 1) and GOLD group cat-
egorization were determined using the mMRC score for 
3,558 patients with available data (Table S1). The C statistic 
(95% CI) for a model using the DOSE index was 0.641 
(0.617–0.664) and that using the GOLD groups was 0.644 
(0.622–0.666) as compared with 0.751 (0.742–0.761) for our 
full-population model.
Discussion
Using a large database of routinely collected electronic health 
records from patients with COPD in the UK, we developed 
and validated a model incorporating eleven variables that 
performed well in predicting two or more COPD exacerba-
tions in the subsequent year (C statistic of 0.751). Sensitivity 
analyses in the subpopulations with no asthma ever recorded 
(C statistic 0.742) and with patient-recorded questionnaire 
data (C statistic 0.745) supported the main results. The 
frequency of exacerbations in the previous year was the major 
predictor of future exacerbation risk. Our findings provide 
evidence that routinely collected health care data can be 
used to predict frequent COPD exacerbations. Moreover, our 
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Table 1 Baseline characteristics of all patients and of the two subpopulations
Characteristics Total population  
(N=16,565)
Subpopulation 1 (no  
asthma ever) (N=9,393)
Subpopulation 2 (with  
symptom data) (N=3,713)
Female sex, n (%) 7,736 (46.7) 4,187 (44.6) 1,623 (43.7)
age, median (IQr) 70 (63–78) 71 (63–78) 71 (58–78)
Weight (kg), mean (sD) 74.4 (18.3) 74.0 (18.2) 76.3 (18.2)
height (m), mean (sD) 1.67 (0.10) 1.67 (0.10) 1.68 (0.10)
BMI, mean (sD) 26.7 (5.8) 26.4 (5.7) 27.1 (5.6)
BMI, n (%)
Underweight (,18.5 kg/m2) 859 (5.2) 550 (5.9) 151 (4.1)
normal ($18.5 and ,25 kg/m2) 6,016 (36.3) 3,503 (37.3) 1,293 (34.8)
Overweight ($25 and ,30 kg/m2) 5,607 (33.8) 3,151 (33.5) 1,278 (34.4)
Obese ($30 kg/m2) 4,083 (24.6) 2,189 (23.3) 991 (26.7)
smoking status, n (%)
never smoker 1,964 (11.9) 761 (8.1) 455 (12.3)
ex-smoker 8,875 (53.6) 4,952 (52.7) 2,220 (59.8)
Current smoker 5,726 (34.6) 3,680 (39.2) 1,038 (28.0)
Pack-years of smoking, median (IQr)a n/a n/a 27.5 (12.5–40.5)
CaT score, median (IQr) n/a n/a 17 (11–23)
CaT score $10, n (%) n/a n/a 3,012 (81.1)
mMrC score available, n (%) 3,558 (95.8)
0–1 1,962 (55.1)
$2 1,596 (44.9)
DOse index score available, n (%) 3,558 (95.8)
#4 3,384 (95.1)
.4 174 (4.9)
FeV1/FVC ratio, mean (sD) 54.4 (10.7) 54.6 (10.6) 53.9 (10.6)
FeV1% predicted, mean (sD) 57.4 (18.8) 57.7 (18.7) 57.8 (18.1)
GOLD airflow limitation (FEV1% predicted), n (%)
1: mild ($80%) 1,847 (11.2) 1,053 (11.2) 370 (10.0)
2: moderate (50%–79%) 8,742 (52.8) 5,002 (53.3) 2,069 (55.7)
3: severe (30%–49%) 4,911 (29.6) 2,755 (29.3) 1,071 (28.8)
4: very severe (,30%) 1,065 (6.4) 583 (6.2) 203 (5.5)
eosinophilia ($500 cells/µl), n (%)
eosinophilia – all patients 1,639 (9.9) 831 (8.8) 336 (9.0)
eosinophilia – noncurrent smokers 1,128 (6.8) 522 (5.6) 253 (6.8)
asthma, n (%) 7,172 (43.3) 0 1,587 (42.7)
eczema, n (%) 3,443 (20.8) 1,748 (18.6) 835 (22.5)
rhinitis, n (%)
allergic 1,245 (7.5) 500 (5.3) 307 (8.3)
nonallergic 965 (5.8) 507 (5.4) 242 (6.5)
nasal polyps, n (%) 421 (2.5) 152 (1.6) 94 (2.5)
Diabetes mellitus, n (%) 3,741 (22.6) 2,029 (21.6) 861 (23.2)
gerD, n (%) 1,940 (11.7) 998 (10.6) 446 (12.0)
Ischemic heart disease, n (%) 3,159 (19.1) 1,844 (19.6) 595 (16.0)
heart failure, n (%) 1,340 (8.1) 806 (8.6) 266 (7.2)
anxiety or depression, n (%) 5,151 (31.1) 2,822 (30.0) 1,078 (29.0)
Charlson comorbidity index, n (%)
0 12,802 (77.3) 7,903 (84.1) 2,927 (78.8)
1–4 2,095 (12.6) 577 (6.1) 474 (12.8)
$5 1,668 (10.1) 913 (9.7) 312 (8.4)
Notes: noncurrent smokers included ex-smokers and never smokers. aPack-years data were available for 3,107 patients.
Abbreviations: BMI, body mass index; CaT, COPD assessment Test; DOse, dyspnea, airway obstruction, smoking status, exacerbations; FeV1/FVC, forced expiratory 
volume in 1 second/forced vital capacity; GERD, gastroesophageal reflux disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IQR, interquartile range; 
mMRC, modified Medical Research Council; n/a, not applicable; SD, standard deviation.
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Table 2 number of exacerbations in baseline and outcome years
Number of  
exacerbations
Total population  
(N=16,565)
Subpopulation 1 (no  
asthma ever) (N=9,393)
Subpopulation 2 (with  
symptom data) (N=3,713)
Baseline year, n (%)
0 8,783 (53.0) 5,406 (57.6) 2,003 (53.9)
1 4,101 (24.8) 2,277 (24.2) 912 (24.6)
2 1,940 (11.7) 950 (10.1) 420 (11.3)
3 900 (5.4) 422 (4.5) 206 (5.5)
$4 841 (5.1) 338 (3.6) 172 (4.6)
Outcome year, n (%)
0 9,347 (56.4) 5,640 (60.0) 2,096 (56.5)
1 3,973 (24.0) 2,245 (23.9) 906 (24.4)
2 1,722 (10.4) 844 (9.0) 398 (10.7)
3 754 (4.6) 339 (3.6) 151 (4.1)
$4 769 (4.6) 325 (3.5) 162 (4.4)
Table 3 Univariable predictors of two or more COPD 
exacerbations in the outcome year in the total population data 
set (n=16,565)
Variable Odds ratio  
(95% CI)
P-value
Female sex 1.25 (1.16–1.35) 9×10-9
age (per 10 years) 1.71 (1.14–2.56) 0.009
age2 (per 10 years) 0.96 (0.93–0.98) 0.003
height (per 10 cm) 0.88 (0.85–0.92) 6×10-10
Body mass index
normal 1.00 0.30
Underweight 1.10 (0.92–1.31) 0.60
Overweight 1.02 (0.93–1.12) 0.45
Obese 1.04 (0.94–1.15)
smoking status
never 1.00 0.23
Former 1.08 (0.95–1.22) 0.48
Current 0.95 (0.84–1.09)
exacerbations in the baseline year
0 1.00 3×10
1 2.55 (2.30–2.84) 5×10
2 4.86 (4.31–5.47) 7×10
3 8.34 (7.17–9.68) 8×10
$4 21.05 (17.90–24.75)
asthma 1.67 (1.55–1.81) 7×10-39
rhinitis
allergic 1.12 (0.97–1.29) 0.13
nonallergic 1.60 (1.38–1.85) 5×10-10
nasal polyps 1.49 (1.19–1.85) 0.0004
gerD 1.37 (1.22–1.53) 3×10-8
anxiety/depression 1.32 (1.22–1.44) 8×10-12
eczema 1.17 (1.06–1.28) 0.001
Diabetes 1.12 (1.02–1.22) 0.01
Ischemic heart disease 1.12 (1.02–1.23) 0.02
heart failure 1.12 (0.98–1.29) 0.09
Charlson comorbidity index
0 1.00
1 1.41 (1.27–1.58) 5×10-10
$2 1.22 (1.08–1.38) 0.002
FeV1% (per 10% decrease) 1.15 (1.12–1.17) 5×10-36
FeV1/FVC (per 10% decrease) 1.17 (1.13–1.22) 4×10-19
Blood eosinophilia
noncurrent smokers 1.43 (1.25–1.64) 7×10-7
Current smokers 0.89 (0.70–1.12) 0.31
Note: noncurrent smokers included ex-smokers and never smokers.
Abbreviations: CI, confidence interval; FEV1/FVC, forced expiratory volume in 
1 second/forced vital capacity; GERD, gastroesophageal reflux disease.
Table 4 Significant multivariable predictors of two or more 
COPD exacerbations in the outcome year in the total population 
data set (n=16,565)
Covariate Odds ratio (95% CI)
exacerbations in the baseline year
0 1.00
1 2.42 (2.18–2.69)
2 4.39 (3.89–4.95)
3 7.28 (6.25–8.48)
$4 17.83 (15.12–21.03)
FeV1% predicted (per 10% decrease) 1.10 (1.07–1.12)
age (per 10 years) 1.43 (0.92–2.23)
age2 (per 10 years) 0.97 (0.93–1.00)
height (per 10 cm) 0.89 (0.85–0.93)
eosinophilia in noncurrent smokers 1.29 (1.10–1.51)
asthma 1.34 (1.23–1.46)
nonallergic rhinitis 1.35 (1.15–1.59)
nasal polyps 1.39 (1.09–1.78)
Ischemic heart disease 1.12 (1.01–1.25)
anxiety or depression 1.11 (1.02–1.22)
gerD 1.18 (1.05–1.34)
Model C statistic (95% CI) 0.751 (0.742–0.761)
Note: noncurrent smokers included ex-smokers and never smokers.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; 
GERD, gastroesophageal reflux disease.
model performed better for predicting COPD exacerbations 
when applied to our heterogeneous study population than 
models using the DOSE index or GOLD groups calculated 
using the mMRC score.
Many other predictive studies have focused on risk of 
death or hospitalization, often among patients with severe 
COPD.13,15,17,19–21 A strength of the current study is the inclu-
sion of all individuals with COPD in a general population 
and all subsequent exacerbations, regardless of whether the 
exacerbation required hospitalization.
Exacerbation rates were relatively low in the study, 
with .50% of patients having no acute exacerbation in 
either the baseline or the outcome years, possibly a result 
of the broadly inclusive eligibility criteria that produced a 
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distribution of COPD severities, from mild to very severe, 
within the study population;27 primary care COPD popula-
tions are recognized as having lower rates of exacerba-
tions than patients enrolled in clinical trials.28 Moreover, 
the relatively low rate of exacerbations seen in this study, 
as compared with past research suggesting mean annual 
rates of 0.8 in mild COPD and 1.2–2.0 in moderate to very 
severe COPD,27 may be a reflection of changes in recent 
years, including better identification of milder COPD, with 
spirometry being broadly undertaken, and more focused 
COPD management in UK primary care.29
A value close to 1 for the C statistic indicates that a model 
has excellent discriminatory power.30 While a C statistic of 
0.75 for our model indicates modest predictive ability, the 
Table 5 Significant multivariable predictors of two or more COPD exacerbations in the outcome year among subpopulations
Covariate OR (95% CI)
Subpopulation 1 (no  
asthma ever) (N=9,393)
Subpopulation 2 (with  
symptom data) (N=3,713)
exacerbations in the baseline year
0 1.00 1.00
1 2.34 (2.02–2.71) 2.17 (1.73–2.71)
2 4.46 (3.75–5.30) 4.26 (3.30–5.51)
3 7.86 (6.31–9.79) 6.49 (4.71–8.93)
$4 18.18 (14.21–23.26) 15.11 (10.57–21.59)
FeV1% predicted (per 10% decrease) 1.09 (1.06–1.14) 1.05 (1.00–1.11)
age (per 10 years) 1.59 (0.81–3.11) 5.45 (1.77–16.78)
age2 (per 10 years) 0.96 (0.91–1.01) 0.89 (0.82–0.96)
height (per 10 cm) 0.86 (0.80–0.91) nI
eosinophilia in noncurrent smokers 1.41 (1.11–1.79) 1.43 (1.04–1.98)
asthma nI 1.19 (1.00–1.43)
nonallergic rhinitis 1.45 (1.14–1.83) nI
nasal polyps 1.52 (1.00–2.32) 1.95 (1.18–3.20)
heart failure 1.30 (1.06–1.60) nI
Diabetes 1.11 (0.97–1.28) nI
anxiety or depression 1.17 (1.03–1.33) nI
gerD 1.22 (1.02–1.46) nI
Female sex nI 1.31 (1.09–1.57)
CaT score (per 10 units) nI 1.28 (1.15–1.42)
Model C statistic 0.742 (0.728–0.756) 0.745 (0.724–0.766)
Note: noncurrent smokers included ex-smokers and never smokers.
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; FEV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; NI, not included 
in the model; Or, odds ratio.
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Figure 2 Calibration plot of observed versus predicted risk using the full 
developmental model (n=16,565).
Figure 3 Calibration plot (25 groups of 108–109 observations) of the observed 
versus predicted risk after applying the model to the validation cohort (n=2,713).
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results of the current study compare favorably with those 
of the earlier studies focused on predicting exacerbations. 
Miravitlles et al31 performed a cross-sectional assessment 
of frequent ($1 per year) exacerbation occurrence among 
627 ambulatory patients with COPD. Significant covariates 
included age, FEV
1
, and chronic mucus hypersecretion, but 
none of these were particularly strong risk factors (OR for 
hypersecretion 1.54), and the predictive ability of the model 
was marginal (C statistic 0.6).
A substantial number of prospective studies have also 
attempted to predict COPD exacerbations. Niewoehner 
et al18 followed 1,829 veterans for 6 months to assess the 
risk of either COPD exacerbation or COPD hospitalization. 
Significant independent predictors for exacerbation included 
older age, FEV
1
, productive cough, previous hospitalization, 
and medications used previously. However, all patients 
had moderate to severe COPD, and the short follow-up 
may have limited the predictive ability of the model, which 
was itself inferior (C statistic 0.67). Hurst et al32 followed 
2,138 patients with COPD for 3 years to assess risk of 
COPD exacerbations requiring antibiotics, corticosteroids, 
or hospitalization. Significant multivariable predictors of two 
or more exacerbations included previous exacerbation, FEV
1
, 
history of GERD, increased white cell count, and respiratory 
health status. Predictive ability of the full model was not 
reported. Bertens et al16 followed 243 patients with COPD for 
24 months to assess the risk of exacerbation occurrence. Their 
multivariable model identified FEV
1
, smoking pack-years, 
history of vascular disease, and previous exacerbations (as a 
dichotomous variable, yes/no) as significant predictors. The 
model C statistic (0.75) suggested good predictive ability, 
but the small sample raises issues as to general applicability 
of these findings, which are mirrored by a marginal external 
validity (validation C statistic 0.66). Bowler et al33 followed 
3,804 patients with COPD for an average of 3 years, identify-
ing ten significant exacerbation predictors, especially FEV
1
, 
St George severity score, and exacerbation in the previous 
year. However, none were strong risk factors (OR 1.19 per 
exacerbation in the previous year), and information on overall 
predictive ability and external validation was not provided.
The largest prospective study conducted to date inclu-
ded ~59,000 patients with COPD from a primary care data-
base and followed them for 1 year. Multivariable logistic 
regression identified many significant predictors of two or 
more exacerbations, including previous exacerbation, air-
flow, level of dyspnea, female sex, and various comorbidities 
(eg, heart failure, renal disease, anxiety, and asthma). Unfor-
tunately, predictive ability of the model was not reported.34
Most recently, Make et al35 followed 3,141 patients from 
several drug trials with a history of $1 COPD exacerbation 
in the previous year in order to predict the 6-month risk of 
an exacerbation requiring corticosteroids or emergency/
hospital visit. Independent predictors from a multivariable 
model included number of maintenance medications, inhaler 
use, exacerbations in the previous year, FEV
1
/FVC ratio, 
female sex, and respiratory health status. The C statistic of 
0.67 suggested only moderate predictive ability.
Our study identified the number of exacerbations in the 
previous year as a significant predictive factor, which was 
borne out by most of the studies cited earlier. Bowler et al33 
and Make et al35 reported only moderately increased risk for 
previous exacerbation, although the latter study used one pre-
vious exacerbation as the reference value (rather than none) 
in patients with at least one previous exacerbation. However, 
Bertens et al16 reported an OR of 5.07 (95% CI 2.55–10.07) for 
at least one exacerbation in the previous year, and Hurst et al32 
reported an OR of 5.72 (95% CI 4.47–7.31) for this same 
measure. Müllerová et al34 reported an exposure–response 
relationship, with one previous exacerbation associated with 
an OR of 3.31 (95% CI 3.12–3.51) and two or more associ-
ated with an OR of 13.64 (12.67–14.68). The findings from 
these latter three studies are consistent with those reported 
in the current study. Furthermore, our results and those 
reported by Müllerová et al34 suggest that risk increases with 
increasing number of previous exacerbations, highlighting 
the importance of obtaining detailed information on this 
variable.
Neither our multivariable model nor most other predictive 
models have identified an independent association between 
smoking and frequent exacerbations in a broad population 
of patients with COPD. This suggests that the impact of 
this variable is dependent on inclusion criteria frequently 
applied to select patients with COPD for controlled trials. 
Any association with smoking may also be ameliorated by 
a so-called “healthy smoker effect”, in which those with 
poorer lung function or frequent exacerbations tend to quit 
smoking, whereas less severely affected patients do not.18 
This suggests that there is a phenotypical propensity to fre-
quent exacerbation that is somewhat independent of other 
risk factors.32,34
A unique finding of the current study was the signifi-
cance of blood eosinophilia as an independent predictor. 
This is consistent with research showing that eosinophils are 
present in 20%–40% of sputum samples from patients with 
stable COPD and that airway eosinophilia increases during 
exacerbation episodes.36 This variable had only a moderate 
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OR of ~1.3, and only among patients not currently smoking, 
so there may be somewhat limited applicability for predict-
ing exacerbations in general. However, the relatively weak 
association with eosinophilia may reflect more active COPD 
management among this population compared with others. 
We conducted a post hoc sensitivity analysis to evaluate 
whether the association between blood eosinophilia and the 
risk of two or more exacerbations would be relevantly differ-
ent after excluding the 17% (n=2,785) of patients with blood 
eosinophil counts measured at an exacerbation. The results 
were not relevantly different after excluding these measure-
ments from the analyses (OR 1.26 [95% CI 1.04–1.52] vs 
1.29 [1.10–1.51] for the full population).
We also identified CAT score as a significant predictor 
for subpopulation 2, which to the best of our knowledge 
has not been reported elsewhere. Indices of COPD severity 
such as the BODE index have been significantly linked to 
future exacerbations,9,37 but these are more complex than the 
simple CAT survey.
A major strength of the current study is the sample size 
of .16,000 patients, which is much larger than most other 
predictive studies. In fact, the population in the current study 
was more than fivefold larger than all but that of Müllerová 
et al.34 However, it is likely that some of the variables retained 
in our final model reached significance primarily because 
of this large sample rather than because of strong biological 
importance. Müllerová et al34 similarly reported relatively 
weak OR for many of their predictors but without information 
on the overall model predictability or the predictive power 
of individual variables.
We identified a number of comorbid predictors, including 
heart disease, GERD, and other respiratory conditions. Con-
ditions such as GERD and heart disease have been identified 
in other follow-up studies,32–34 whereas risk factors such as 
nasal polyps and rhinitis appear unique to the current study. 
These findings highlight the potentially complex relation-
ship that may exist between COPD and other conditions. 
Although these comorbidities were not strong risk factors 
(OR 1.1–1.4), their importance would likely improve in a 
model of newly diagnosed COPD patients without history of 
exacerbation. Of course, some of these significant predictors 
may have been driven by the large sample size.
Asthma is recognized as an important comorbid condition 
that increases disability and risk of exacerbation among those 
with COPD.38,39 Asthma was also a significant independent 
predictor in the current study. However, the OR for asthma 
was of similar magnitude as that for several other variables, 
and excluding patients with any record of asthma did not 
appreciably change the model. Such findings may reflect an 
overuse of the asthma “label”, especially in the past. We 
applied a very sensitive definition to select the subpopulation 
of patients without overlapping asthma, namely, the recording 
of any Read code that could indicate the general practitioner 
(GP) was considering asthma, which explains the relatively 
high proportion of patients reported with COPD and con-
comitant asthma. We cannot exclude the possibility of some 
patients being wrongly diagnosed with asthma by the GP or, 
conversely, of some patients having undiagnosed asthma.
Differences between the current study and previous 
clinical research may partially reflect the populations 
studied. Clinical trials typically enroll restricted populations 
with more severe disease, often with a greater frequency of 
exacerbation at baseline.16,35 The current population better 
reflects the broader landscape of patients with COPD treated 
in routine primary care practice in the UK. Nonetheless, we 
cannot rule out the possibility of selection bias. For example, 
we required an FEV
1
/FVC ratio of ,0.7 for study inclusion. 
Because spirometry is not universally available in primary 
care settings, 11,658 of 37,224 (31%) otherwise potentially 
eligible patients did not have spirometry results and hence 
were excluded. With regard to the requirement for blood 
eosinophil count, full blood count measurements are very 
common among patients with COPD and were available for 
86% of patients evaluated (43,436 of 50,716 patients with 
COPD and no other chronic respiratory disease).
Our aim was to evaluate the predictive value of routinely 
collected data. Although other parameters of eosinophilic 
inflammation, such as sputum eosinophils or exhaled nitric 
oxide, may have improved the predictive performance of the 
model, these measurements are generally unavailable in gen-
eral practice and hence were not included in our model. The 
current study used electronic records from primary care pro-
viders, which are a readily available data source. However, 
it is possible that outcomes such as hospital and emergency 
admissions may be underrepresented in the data.
The current study was validated both internally and exter-
nally, with good concordance when the multivariable model 
was applied to an external sample. However, this does not 
guarantee universal generalizability given that our external 
sample arose from the same patient population as the sample 
used for model development. Further study is needed to vali-
date the model in other patient populations as well.
Conclusion
Routine, electronic medical record data available from most 
GP clinical systems can be used to identify patients with 
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COPD at risk of two or more exacerbations the subsequent 
year. Our model could be used to profile patients with COPD, 
or to underpin decision support tools, in general practice. 
The number of exacerbations in the preceding year showed 
a strong exposure–response relationship, highlighting the 
importance of detailed information on patients’ exacerba-
tion history. The findings also suggest that CAT score and 
eosinophilia may be convenient markers of future exacerba-
tion, at least in some populations.
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Supplementary materials
The formula: Risk of $2 COPD exacerbations within the 
next 12 months =1/(1+ exp(-0.7306+0.8840×1 previous 
exacerbation in last 12 months +1.4786×2 previous exacer-
bations in last 12 months +1.9857×3 previous exacerbations 
in last 12 months +2.8811× $4 previous exacerbations 
in last 12 months -0.0093× FEV
1
% predicted +0.0360× 
age -0.0004× age2 -1.2194× height (in meter) +0.2518× (blood 
eosinophil count $400/µL in a patient who is not currently 
smoking) +0.2953× any evidence of asthma ×0.3018× history of 
nonallergic rhinitis +0.3298× history of nasal polyps +0.1164× 
history of ischemic heart disease +0.1071× history of anxiety 
of depression +0.1689× history of GERD).
Example: a person aged 70 years currently smoking with 
height of 1.80 m and FEV
1
 of 60% of predicted, without a 
history of previous exacerbations in the last 12 months and 
no history of comorbidities, has a calculated risk of 0.064 
(6.4%) of two or more exacerbations in the next year.
Table S2 Baseline characteristics of the validation cohort
Characteristics Total population 
(N=2,713)
Female sex, n (%) 1,237 (45.6)
age, median (IQr) 71 (64–79)
Weight (kg), mean (sD) 74.0 (18.2)
height (m), mean (sD) 1.67 (0.10)
Body mass index, mean (sD) 26.6 (5.7)
Body mass index, n (%)
Underweight (,18.5 kg/m2) 157 (5.8)
normal ($18.5 and ,25 kg/m2) 1,006 (37.1)
Overweight ($25 and ,30 kg/m2) 904 (33.3)
Obese ($30 kg/m2) 646 (23.8)
smoking status, n (%)
never smoker 341 (12.6)
ex-smoker 1,365 (50.3)
Current smoker 1,007 (37.1)
FeV1/FVC ratio, mean (sD) 54.5 (11.0)
FeV1% predicted, mean (sD) 57.4 (19.9)
GOLD airflow limitation (FEV1% predicted), n (%)
1: mild ($80%) 331 (12.2)
2: moderate (50%–79%) 1,345 (49.6)
3: severe (30%–49%) 830 (30.6)
4: very severe (,30%) 207 (7.6)
eosinophilia ($500 cells/µl), n (%)
eosinophilia – all patients 252 (9.3)
eosinophilia – noncurrent smokers 199 (7.3)
asthma, n (%) 1,335 (49.2)
eczema, n (%) 560 (20.6)
rhinitis, n (%)
allergic 225 (8.3)
nonallergic 171 (6.3)
nasal polyps, n (%) 59 (2.2)
Ischemic heart disease, n (%) 655 (24.1)
anxiety or depression, n (%) 908 (33.5)
gerD 358 (13.2)
Abbreviations: IQr, interquartile range; sD, standard deviation; FeV1/FVC, forced 
expiratory volume in 1 second/forced vital capacity; gOlD, global Initiative for 
Chronic Obstructive Lung Disease; GERD, gastroesophageal reflux disease.
Table S1 Baseline mMrC scores, DOse index scores, and 
gOlD groups based on mMrC score
Subpopulation 2 (with 
symptom data) (N=3,558)
mMrC score
0 558 (15.7)
1 1,404 (39.5)
2 802 (22.5)
3 539 (15.1)
4 255 (7.2)
DOse index score
0 846 (23.8)
1 1,070 (30.1)
2 711 (20.0)
3 469 (13.2)
4 288 (8.1)
.4 174 (4.9)
gOlD category
a 1,213 (34.1)
B 661 (18.6)
C 749 (21.1)
D 935 (26.3)
Notes: mMrC data (hence DOse index scores and gOlD category based on 
mMrC)1-3 were available for 3,558 (95.8%) of 3,713 patients in subpopulation 2. 
Data are presented as n (% of 3,558). gOlD categories were calculated using 
mMrC, exacerbations, and FeV1.
Abbreviations: DOse, dyspnea, airway obstruction, smoking status, exacerbations; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified 
Medical research Council; FeV1, forced expiratory volume in 1 second.
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